Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lipoproteins | 6 | 2023 | 881 | 1.650 |
Why?
|
Triglycerides | 7 | 2023 | 2461 | 1.620 |
Why?
|
Benzoxazoles | 2 | 2024 | 90 | 1.460 |
Why?
|
Peripheral Arterial Disease | 7 | 2023 | 1273 | 1.290 |
Why?
|
Cardiovascular Diseases | 25 | 2024 | 15502 | 1.120 |
Why?
|
C-Reactive Protein | 18 | 2023 | 3826 | 1.000 |
Why?
|
Diabetes Mellitus, Type 2 | 25 | 2024 | 12149 | 0.970 |
Why?
|
Gangrene | 1 | 2024 | 91 | 0.920 |
Why?
|
Cholesterol, LDL | 6 | 2020 | 2382 | 0.860 |
Why?
|
Butyrates | 2 | 2024 | 169 | 0.810 |
Why?
|
Hyperhomocysteinemia | 1 | 2021 | 118 | 0.720 |
Why?
|
Diabetic Foot | 1 | 2024 | 380 | 0.700 |
Why?
|
Peripheral Vascular Diseases | 3 | 2009 | 488 | 0.680 |
Why?
|
Hypertriglyceridemia | 2 | 2021 | 293 | 0.660 |
Why?
|
Ankle Brachial Index | 1 | 2020 | 163 | 0.660 |
Why?
|
Homocysteine | 3 | 2021 | 638 | 0.650 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2017 | 1723 | 0.650 |
Why?
|
Intercellular Adhesion Molecule-1 | 6 | 2020 | 1126 | 0.630 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 175 | 0.550 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 283 | 0.500 |
Why?
|
Peptide Fragments | 4 | 2017 | 5112 | 0.490 |
Why?
|
Hypolipidemic Agents | 1 | 2019 | 609 | 0.470 |
Why?
|
Troponin T | 3 | 2017 | 780 | 0.460 |
Why?
|
Incidence | 20 | 2024 | 21355 | 0.450 |
Why?
|
Inflammation | 10 | 2023 | 10774 | 0.450 |
Why?
|
Atherosclerosis | 5 | 2023 | 3407 | 0.440 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1809 | 0.440 |
Why?
|
Cholesterol | 2 | 2023 | 2905 | 0.400 |
Why?
|
Anticholesteremic Agents | 2 | 2018 | 966 | 0.390 |
Why?
|
Interleukin-6 | 8 | 2018 | 3208 | 0.380 |
Why?
|
Insulin | 5 | 2024 | 6597 | 0.380 |
Why?
|
Lipoproteins, VLDL | 4 | 2021 | 201 | 0.380 |
Why?
|
Hyperinsulinism | 2 | 2006 | 400 | 0.380 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1866 | 0.380 |
Why?
|
Eicosapentaenoic Acid | 1 | 2015 | 561 | 0.370 |
Why?
|
Adiponectin | 2 | 2019 | 1113 | 0.360 |
Why?
|
Dyslipidemias | 1 | 2018 | 868 | 0.360 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 6403 | 0.360 |
Why?
|
Risk Assessment | 19 | 2024 | 23996 | 0.340 |
Why?
|
Prospective Studies | 27 | 2023 | 54423 | 0.340 |
Why?
|
Diabetes Complications | 4 | 2011 | 1315 | 0.330 |
Why?
|
Risk Factors | 36 | 2023 | 74213 | 0.320 |
Why?
|
Docosahexaenoic Acids | 1 | 2015 | 907 | 0.300 |
Why?
|
Middle Aged | 54 | 2024 | 220921 | 0.300 |
Why?
|
Hypoglycemic Agents | 3 | 2017 | 3085 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 10212 | 0.280 |
Why?
|
Metformin | 2 | 2017 | 906 | 0.280 |
Why?
|
Vitamin D | 2 | 2024 | 3303 | 0.280 |
Why?
|
Coronary Disease | 5 | 2005 | 5914 | 0.270 |
Why?
|
Methotrexate | 3 | 2020 | 1719 | 0.270 |
Why?
|
Blood Glucose | 7 | 2024 | 6391 | 0.260 |
Why?
|
Aspirin | 4 | 2015 | 3133 | 0.250 |
Why?
|
Female | 59 | 2024 | 392705 | 0.250 |
Why?
|
Insulin Resistance | 7 | 2024 | 3964 | 0.240 |
Why?
|
Vitamin E | 3 | 2015 | 872 | 0.240 |
Why?
|
Lipoprotein(a) | 3 | 2022 | 480 | 0.230 |
Why?
|
Arteriosclerosis | 3 | 2004 | 1055 | 0.230 |
Why?
|
Humans | 76 | 2024 | 761596 | 0.230 |
Why?
|
Women's Health | 5 | 2015 | 2065 | 0.220 |
Why?
|
Dietary Supplements | 2 | 2024 | 3415 | 0.220 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2024 | 1390 | 0.220 |
Why?
|
Case-Control Studies | 13 | 2021 | 22176 | 0.210 |
Why?
|
Proinsulin | 1 | 2003 | 135 | 0.210 |
Why?
|
C-Peptide | 1 | 2024 | 440 | 0.210 |
Why?
|
Sex Factors | 7 | 2021 | 10554 | 0.210 |
Why?
|
Obesity | 6 | 2019 | 12947 | 0.200 |
Why?
|
Double-Blind Method | 10 | 2024 | 12341 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2004 | 422 | 0.200 |
Why?
|
Apolipoproteins | 2 | 2021 | 326 | 0.200 |
Why?
|
Medicare | 1 | 2020 | 6770 | 0.190 |
Why?
|
Interleukin-1beta | 3 | 2018 | 999 | 0.190 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 2024 | 0.190 |
Why?
|
Chylomicron Remnants | 1 | 2021 | 3 | 0.190 |
Why?
|
Cholesterol, HDL | 4 | 2020 | 1814 | 0.190 |
Why?
|
Fibric Acids | 1 | 2021 | 27 | 0.180 |
Why?
|
Postmenopause | 3 | 2006 | 2513 | 0.180 |
Why?
|
Cohort Studies | 11 | 2020 | 41495 | 0.180 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39106 | 0.180 |
Why?
|
Time Factors | 7 | 2024 | 39969 | 0.180 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12463 | 0.170 |
Why?
|
Colchicine | 1 | 2021 | 259 | 0.170 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 691 | 0.170 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1208 | 0.170 |
Why?
|
Tissue Plasminogen Activator | 2 | 2005 | 1164 | 0.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3246 | 0.160 |
Why?
|
Lipoproteins, HDL | 3 | 2020 | 676 | 0.160 |
Why?
|
Smoking | 4 | 2015 | 9053 | 0.160 |
Why?
|
Aged | 30 | 2024 | 169310 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 6312 | 0.160 |
Why?
|
United States | 14 | 2021 | 72340 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2023 | 771 | 0.150 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1787 | 0.140 |
Why?
|
Body Mass Index | 11 | 2020 | 12953 | 0.140 |
Why?
|
Calgranulin B | 2 | 2007 | 86 | 0.130 |
Why?
|
Blood Pressure | 2 | 2011 | 8481 | 0.130 |
Why?
|
Cerebrovascular Disorders | 1 | 2023 | 1474 | 0.130 |
Why?
|
Adipose Tissue | 4 | 2019 | 3313 | 0.130 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2018 | 509 | 0.130 |
Why?
|
Diabetes Mellitus | 4 | 2016 | 5841 | 0.130 |
Why?
|
Leptin | 2 | 2016 | 1597 | 0.130 |
Why?
|
Male | 29 | 2024 | 360846 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2021 | 1475 | 0.120 |
Why?
|
Hypertension | 2 | 2011 | 8540 | 0.120 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 250 | 0.110 |
Why?
|
Diet, Mediterranean | 1 | 2020 | 740 | 0.110 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11461 | 0.110 |
Why?
|
Fasting | 3 | 2006 | 1603 | 0.110 |
Why?
|
Predictive Value of Tests | 6 | 2015 | 15266 | 0.110 |
Why?
|
Lower Extremity | 1 | 2021 | 1202 | 0.110 |
Why?
|
Risk | 3 | 2013 | 9610 | 0.100 |
Why?
|
Molecular Weight | 2 | 2011 | 2186 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2024 | 64685 | 0.100 |
Why?
|
Heart Atria | 2 | 2008 | 1345 | 0.100 |
Why?
|
Research Report | 1 | 2015 | 367 | 0.100 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 350 | 0.100 |
Why?
|
Lipids | 3 | 2019 | 3341 | 0.090 |
Why?
|
Statistics, Nonparametric | 3 | 2018 | 2850 | 0.090 |
Why?
|
Disease Management | 2 | 2020 | 2508 | 0.090 |
Why?
|
Fluorobenzenes | 1 | 2012 | 179 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15936 | 0.090 |
Why?
|
Age Factors | 5 | 2021 | 18399 | 0.090 |
Why?
|
Placebos | 2 | 2020 | 1667 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1373 | 0.090 |
Why?
|
Body Weight | 4 | 2014 | 4618 | 0.080 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 58 | 0.080 |
Why?
|
Systole | 1 | 2011 | 936 | 0.080 |
Why?
|
Drug Combinations | 1 | 2015 | 2048 | 0.080 |
Why?
|
Diastole | 1 | 2011 | 782 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8002 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.080 |
Why?
|
Immunoassay | 1 | 2012 | 745 | 0.080 |
Why?
|
Polysaccharides | 1 | 2015 | 1014 | 0.080 |
Why?
|
Estrogen Receptor beta | 1 | 2009 | 168 | 0.080 |
Why?
|
Death, Sudden, Cardiac | 1 | 2016 | 1555 | 0.080 |
Why?
|
Life Style | 3 | 2014 | 3917 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 344 | 0.070 |
Why?
|
Calgranulin A | 1 | 2007 | 80 | 0.070 |
Why?
|
Antioxidants | 1 | 2015 | 1668 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 3415 | 0.070 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 897 | 0.070 |
Why?
|
Neoplasms | 2 | 2015 | 22173 | 0.070 |
Why?
|
Forms and Records Control | 1 | 2007 | 158 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2012 | 4352 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 2751 | 0.070 |
Why?
|
Prognosis | 3 | 2021 | 29629 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4176 | 0.060 |
Why?
|
Heptanoic Acids | 1 | 2007 | 344 | 0.060 |
Why?
|
Anthropometry | 2 | 2008 | 1349 | 0.060 |
Why?
|
Pravastatin | 1 | 2007 | 392 | 0.060 |
Why?
|
Cardiotonic Agents | 1 | 2008 | 539 | 0.060 |
Why?
|
Statistics as Topic | 1 | 2011 | 2358 | 0.060 |
Why?
|
Body Size | 1 | 2008 | 463 | 0.060 |
Why?
|
Logistic Models | 5 | 2016 | 13255 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 583 | 0.060 |
Why?
|
Odds Ratio | 4 | 2007 | 9647 | 0.060 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 5127 | 0.060 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 518 | 0.060 |
Why?
|
Fibrinogen | 1 | 2008 | 888 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3162 | 0.050 |
Why?
|
Confidence Intervals | 3 | 2018 | 2927 | 0.050 |
Why?
|
Reference Values | 4 | 2016 | 4920 | 0.050 |
Why?
|
Carotenoids | 1 | 2006 | 621 | 0.050 |
Why?
|
Lipoproteins, LDL | 2 | 2020 | 642 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4244 | 0.050 |
Why?
|
Social Class | 1 | 2011 | 2004 | 0.050 |
Why?
|
Diet | 3 | 2020 | 8075 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2011 | 6228 | 0.050 |
Why?
|
Sulfonamides | 1 | 2012 | 1979 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 17904 | 0.050 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 436 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 803 | 0.050 |
Why?
|
Creatinine | 1 | 2008 | 1899 | 0.050 |
Why?
|
Lovastatin | 1 | 2002 | 115 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2008 | 12059 | 0.050 |
Why?
|
Pyrroles | 1 | 2007 | 1125 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9177 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 12690 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1186 | 0.050 |
Why?
|
Solubility | 1 | 2002 | 1091 | 0.040 |
Why?
|
Comorbidity | 2 | 2007 | 10508 | 0.040 |
Why?
|
Adult | 11 | 2021 | 221210 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10721 | 0.040 |
Why?
|
Pyrimidines | 1 | 2012 | 3028 | 0.040 |
Why?
|
Apolipoprotein B-100 | 1 | 2020 | 157 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2019 | 58984 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 3769 | 0.040 |
Why?
|
Migraine Disorders | 1 | 2012 | 1703 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 11904 | 0.040 |
Why?
|
Premedication | 1 | 2020 | 246 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2011 | 2057 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 2020 | 299 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2015 | 14608 | 0.040 |
Why?
|
Antigens | 1 | 2004 | 1443 | 0.040 |
Why?
|
Glucose Intolerance | 1 | 2002 | 575 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2021 | 543 | 0.040 |
Why?
|
Patient Compliance | 1 | 2008 | 2690 | 0.040 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2020 | 269 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 199 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9420 | 0.040 |
Why?
|
Abdomen | 1 | 2003 | 1128 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2003 | 751 | 0.040 |
Why?
|
Policy | 1 | 2021 | 509 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 12794 | 0.030 |
Why?
|
Islets of Langerhans | 1 | 2003 | 1341 | 0.030 |
Why?
|
American Heart Association | 1 | 2021 | 1039 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14665 | 0.030 |
Why?
|
Weight Gain | 1 | 2006 | 2348 | 0.030 |
Why?
|
Blood Platelets | 1 | 2006 | 2479 | 0.030 |
Why?
|
Echocardiography | 1 | 2008 | 4989 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2006 | 2118 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 803 | 0.030 |
Why?
|
Menopause | 1 | 2003 | 1646 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 290 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2007 | 2190 | 0.030 |
Why?
|
Homeostasis | 1 | 2024 | 3323 | 0.030 |
Why?
|
Regression Analysis | 1 | 2003 | 6345 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2021 | 1902 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2477 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 545 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 7828 | 0.020 |
Why?
|
Body Height | 2 | 2008 | 1570 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1612 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2116 | 0.020 |
Why?
|
Adiposity | 1 | 2020 | 1879 | 0.020 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 18 | 0.020 |
Why?
|
Thrombosis | 1 | 2004 | 2942 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6864 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2003 | 4028 | 0.020 |
Why?
|
Inflammation Mediators | 2 | 2011 | 1886 | 0.020 |
Why?
|
Sweetening Agents | 1 | 2012 | 290 | 0.020 |
Why?
|
Stroke | 2 | 2018 | 9758 | 0.020 |
Why?
|
Exercise | 1 | 2006 | 5890 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2005 | 26129 | 0.020 |
Why?
|
Body Surface Area | 1 | 2008 | 197 | 0.020 |
Why?
|
Vitamins | 1 | 2015 | 1635 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3242 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 821 | 0.020 |
Why?
|
Xanthophylls | 1 | 2006 | 94 | 0.020 |
Why?
|
Lutein | 1 | 2006 | 123 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2005 | 6938 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.020 |
Why?
|
Disease Progression | 1 | 2002 | 13510 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3810 | 0.010 |
Why?
|
beta Carotene | 1 | 2006 | 523 | 0.010 |
Why?
|
Bundle-Branch Block | 1 | 2006 | 276 | 0.010 |
Why?
|
Reference Standards | 1 | 2008 | 1003 | 0.010 |
Why?
|
Educational Status | 1 | 2011 | 2522 | 0.010 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 898 | 0.010 |
Why?
|
Acute Disease | 2 | 2006 | 7237 | 0.010 |
Why?
|
Adolescent | 4 | 2019 | 88326 | 0.010 |
Why?
|
Income | 1 | 2011 | 1877 | 0.010 |
Why?
|
Lectins, C-Type | 1 | 2006 | 585 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7391 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2713 | 0.010 |
Why?
|
Myocardium | 1 | 2015 | 4725 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8833 | 0.010 |
Why?
|
Hemostasis | 1 | 2005 | 467 | 0.010 |
Why?
|
Stroke Volume | 2 | 2006 | 5496 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 678 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3606 | 0.010 |
Why?
|
Megakaryocytes | 1 | 2006 | 567 | 0.010 |
Why?
|
International Classification of Diseases | 1 | 2007 | 910 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2395 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16592 | 0.010 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 807 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 983 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2224 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4576 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2007 | 2064 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15843 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 2006 | 1407 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6180 | 0.010 |
Why?
|
Antigens, CD | 1 | 2006 | 4001 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15733 | 0.010 |
Why?
|
Mice | 2 | 2016 | 81539 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20100 | 0.010 |
Why?
|
Animals | 3 | 2016 | 168475 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 5872 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3879 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 12723 | 0.010 |
Why?
|
Electrocardiography | 1 | 2006 | 6377 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 14033 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 59260 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 7593 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9490 | 0.010 |
Why?
|
Child | 2 | 2008 | 80158 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2006 | 22174 | 0.000 |
Why?
|
Infant | 1 | 2008 | 36193 | 0.000 |
Why?
|
Child, Preschool | 1 | 2008 | 42232 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2008 | 80647 | 0.000 |
Why?
|